Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASTRAL-2: Epclusa vs Sofosbuvir+Ribavirin in Genotype 2 HCV
NCT02220998Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Sep 2014
- Primary completion
- Jul 2015
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 2
01
Overview
A Phase 3 trial of velpatasvir in chronic hepatitis C genotype 2, sponsored by Gilead Sciences. Started Sep 2014; status: completed.
02
Drugs
velpatasvir
03
Conditions
chronic hepatitis C genotype 2
Beyond the preview
Go deeper on NCT02220998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02220998.